Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. · Prostate Cancer
Phase 3
Completed
387
2026-06
Industry sponsor intelligence
Sumitomo Pharma America, Inc.Clinical Pipeline.
Lead-sponsor view of Sumitomo Pharma America, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 1
- Avg enrollment
- 218
Pipeline overview
Programs by phase and activity.
Velocity
Sumitomo Pharma America, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Leuprolide → | 1 | 0 | 0 | 1 | 0 | 0 |
| Degarelix → | 1 | 1 | 0 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc. · Metastatic Castration-Resistant Prostate Cancer · Metastatic Castration-Sensitive Prostate Cancer
Phase 1
Completed
48
2025-08
Search sponsor records
All Sumitomo Pharma America, Inc. studies.
This page groups studies where Sumitomo Pharma America, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT05605964Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateJun 15, 2026NCT04666129Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerAug 17, 2025